Is West Pharmaceutical Services Stock Outperforming the Nasdaq?

Is West Pharmaceutical Services Stock Outperforming the Nasdaq?

Wed, September 16, 2026 at 2:50 PM GMT+3 2 min read

• WST +1.27%
• ^IXIC +1.69%

Exton, Pennsylvania-based West Pharmaceutical Services, Inc. (WST) designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products. Valued at $25.7 billion by market cap, the company's technologies include the design and manufacture of packaging components, research and development of drug delivery systems, and contract laboratory services and other services.

Companies worth $10 billion or more are generally described as "large-cap stocks," and WST perfectly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical instruments & supplies industry. WST stands out as a market leader with a diversified portfolio serving pharma and healthcare.

More News from Barchart

Despite its notable strength, WST slipped 5.4% from its 52-week high of $386, achieved on Jul. 23. Over the past three months, WST stock gained 10.1%, outperforming the Nasdaq Composite's ($NASX) 2.6% losses during the same time frame.

Shares of WST rose 32.7% on a YTD basis and climbed 41.7% over the past 52 weeks, outperforming NASX's YTD gains of 11.8% and 16.3% returns over the last year.

To confirm the bullish trend, WST has been trading above its 50-day moving average since late March, with slight fluctuations. The stock has been trading above its 200-day moving average since early April.

WST's outperformance was driven by its Proprietary Products portfolio, particularly high-value components for biologics and biosimilars. Growth was supported by strong participation in new biologic launches, rising demand for advanced containment solutions, and accelerated customer upgrades tied to stricter regulatory standards. GLP-1 therapies emerged as a key growth engine with broad-based demand, while operational excellence helped recover from a prior disruption and meet strong orders. The shift toward higher-value self-injection platforms and a favorable product mix is also supporting margin expansion.

In the competitive arena of medical instruments & supplies, Stevanato Group S.p.A. (STVN) has lagged behind WST, with a 7.1% uptick on a YTD basis and 17.9% losses over the past 52 weeks.

Wall Street analysts are bullish on WST's prospects. The stock has a consensus "Strong Buy" rating from the 18 analysts covering it, and the mean price target of $401.65 suggests a potential upside of 10% from current price levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com